Patient Samples Fuel Development of Innovative Test to Diagnose Early Lyme Disease

Lyme Disease Biobank

BAL Leading the Way Series

 

Lyme Disease Biobank

 

A new type of Lyme disease test aimed at early-stage infection detection is hitting doctors’ offices, and we all should thank Lyme patients for making this happen. This test named T-Detect Lyme, was recently unveiled by Adaptive Biotechnologies, and is an advanced indirect-detection blood test that allows for detection of an acute Lyme infection earlier than antibody response tests.

Adaptive Biotechnologies using Lyme Disease Biobank samples
Courtesy Adaptive Biotechnologies

Our Lyme Disease Biobank (LDB) and Dr. John Aucott’s SLICE Lab at Johns Hopkins University provided the Lyme patient blood samples for Adaptive’s new T-Detect Lyme test development. The LDB, a program of Bay Area Lyme, was created in 2014 and began collecting patient samples in 2015 specifically to drive this form of diagnostic innovation. By engaging Lyme patients and providing well-characterized samples to approved researchers and partnering with innovative organizations like Adaptive, the LDB research engine is now delivering long-planned-for results.

“This breakthrough from Adaptive validates the power of patient-driven research. Without the participation of patients who gave blood to our Lyme Disease Biobank, this impactful new test could not have been developed,” commented Linda Giampa, executive director, Bay Area Lyme Foundation. “We wish to thank all the patients who came forward to participate in this important program and to encourage others to give samples.”

Fueling the Research Engine

Lyme Disease Biobank

BAL Leading the Way Series

 

How a chance meeting and the harnessing of big data led to a research initiative that’s finding answers in Lyme and tick-borne disease

Many different groups comprise the Lyme disease community including patients, their families, healthcare providers, researchers and nonprofit organizations. These nonprofit organizations and foundations may differ in size, structure, fiscal basis, focus and approach, but in one important aspect they are united: the search for answers.

This search for answers in the realm of Lyme and tick-borne diseases has served as a unifying driver, even when dissent and controversy has sometimes fragmented the Lyme community.  And despite what seems to be a constant uphill battle for recognition and legitimacy of Lyme and tick-borne infections, many believe that we’re on the brink of major breakthroughs to help patients and doctors unlock the medical mysteries that make these infectious diseases so confounding. Two people cautiously optimistic about where we are in the search for answers about Lyme are Liz Horn, PhD, MBI, Principal Investigator, Lyme Disease Biobank, and Lorraine Johnson, JD, MBA, Chief Executive Officer, LymeDisease.org and Principal Investigator MyLymeData.

Calling All Scientists: Bay Area Lyme Foundation Now Accepting Applications for 2022 Emerging Leader Award

ELA winner Michael Rout

FOR IMMEDIATE RELEASE

Calling All Scientists: Bay Area Lyme Foundation Now Accepting Applications for 2022 Emerging Leader Award 

Grant aims to inspire new research for the diagnosis and treatment of Lyme disease

PORTOLA VALLEY, California, December 6, 2021—Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the US, is announcing a call for entries for their 2022 Emerging Leader Awards (ELA), which recognize U.S. researchers from academia or the private sector who bring new approaches to the field of Lyme disease and embody the future of Lyme disease research leadership. At least two grants in the amount $100,000 each will be awarded. Proposals must have a defined scientific approach and rationale that can advance diagnostics or treatments for Lyme disease, and applicants are encouraged to bring innovative learnings from other therapeutic areas to their research projects. Applications will be accepted through March 15, 2022, at midnight Pacific Time. The full criteria and application for this grant award can be found here.

“The world is seeing firsthand the damage that infections can cause—both in acute and chronic forms. Just has COVID has encouraged collaboration, we hope that existing Lyme scientists as well as scientists from other disease areas will apply for this grant, offering new hypotheses and technologies to diagnose and treat Lyme and other tick-borne disease,” said Wendy Adams, research grant director, Bay Area Lyme Foundation. 

How Do You Build a Biobank to Solve the Problem of Lyme Disease? Literally – One Tick Bite at a Time

Lyme Disease Biobank

Science is all about asking questions and finding answers. It attracts the curious, the driven, the questioners and fact seekers—the people who won’t accept the status quo and who are always pushing to learn more. If we keep asking science the right questions, we’re bound to get to the right answers eventually. It’s simple, right?

Unfortunately, not. As with everything about Lyme disease the answers to the questions are not so simple. Lyme is a complicated, nuanced disease with many challenging attributes, so much so that even the most experienced clinicians and medical researchers struggle to understand the many ways the infection impacts the human body. So, if you’re going to try and solve the puzzle of Lyme disease, where is the best place to start? How do you get all the pieces in place to move the needle to solve the complexity of this disease?

Enter Bay Area Lyme Foundation and Principal Investigator, Liz Horn PhD, MBI. When they were planning this project, they asked research scientists in the field of Lyme disease what were their big obstacles to finding out more about Lyme? What did scientists need so that they could start chipping away at the conundrum of this horrible disease?

Bay Area Lyme Foundation Selects National Winners of the 2021 Emerging Leader Awards to Advance Research for the Diagnosis and Treatment of Lyme Disease

2021 Emerging Leader Awards

FOR IMMEDIATE RELEASE

Media Contact:
Tara DiMilia, 908-947-0500, tara.dimilia@TMstrat.com

Bay Area Lyme Foundation Selects National Winners of the 2021 Emerging Leader Awards to Advance Research for the Diagnosis and Treatment of Lyme Disease

Brandon Jutras, PhD of Virginia Tech, Nitya Ramadoss, PhD of Stanford University and Michael P. Rout, PhD of The Rockefeller University are this year’s recipients

PORTOLA VALLEY, Calif., July 6th, 2021—Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the U.S., announces the recipients of the 2021 Emerging Leader Awards (ELA), which are designed to support promising scientists who represent the future of Lyme disease research leadership. Michael P. Rout, PhD of The Rockefeller University will receive $250,000 for his work with nanobodies to develop a sensitive point-of-care diagnostic. Brandon Jutras, PhD of Virginia Tech and Nitya Ramadoss, PhD of Stanford University will each receive $100,000 toward the development of a novel direct-detection diagnostic approach for Lyme disease and a novel therapeutic based on B-cell mapping, respectively. Lyme disease is a potentially disabling infection diagnosed in nearly half a million Americans each year.

“As there is not a diagnosis or treatment that works for all patients, there is a critical need to develop direct-detection diagnostics as well as treatments that can prevent the development of persistent Lyme disease, and we are excited to support these novel approaches that have shown success in other areas,” said Linda Giampa, executive director, Bay Area Lyme Foundation.

Two of the award winners will utilize biological samples from the Lyme Disease Biobank, a program of the Bay Area Lyme Foundation, to collect well-characterized human tissue, blood and urine specimens to accelerate research of Lyme disease and other tick-borne infections.

The Mysterious History of Tick-borne Diseases and How We Can Stem the Epidemic

Kris Newby

Kris Newby, author of Bitten: The Secret History of Lyme Disease and Biological Weapons, senior producer of the Lyme disease documentary, Under Our Skin, discusses her Lyme history, her extensive research into tick-borne diseases in the USA and where we find ourselves today in this new pandemic world. Ticktective Video and Podcast Editor: Kiva Schweig.

First Female US Air Force Thunderbird Pilot and Her Fiercest Battle Yet

Ticktective Podcasts

Col. Nicole Malachowski

Col. Nicole Malachowski, first female Thunderbird pilot, National Women’s Hall of Famer, and Former Deputy Director for US Air Force Readiness and Training for the Office of the Under Secretary of Defense for Personnel and Readiness, and Bay Area Lyme Foundation Ambassador shares her challenging journey from military fighter to Lyme warrior. Ticktective Video and Podcast Editor: Kiva Schweig.

Proof of Persistent Lyme

Ticktective Podcasts

Monica Embers, PhD

Monica Embers, PhD, Associate Professor of Microbiology and Immunology at the Tulane National Primate Research Center and Bay Area Lyme Scientific Advisory Board member discusses xenodiagnosis, Borrelia persistence, and her ongoing research in non-human primates. Ticktective Video and Podcast Editor: Kiva Schweig.

Finding Strength and Positivity Through Hardship

Allyshia Gupta

Miss California USA 2020 and Bay Area Lyme Ambassador, Allyshia Gupta, shares her personal story of finding herself through hardship and loss, and the importance of service as a source of strength. Ticktective Video and Podcast Editor: Kiva Schweig.

Nanotrap® Urine Test for Lyme Borreliosis

– Wendy Adams, Research Grant Director, Bay Area Lyme Foundation

 

Bay Area Lyme has a goal to leverage the entrepreneurial spirit and innovation of Silicon Valley in order to catalyze novel projects around the country. Our belief is that the application of cutting-edge technologies will have a dramatic impact on making Lyme disease easy to diagnose and simple to cure. We collaborate with world-class scientists focused on Lyme projects which leverage knowledge from other fields of medicine and research. We also prioritize engagement with the investment and biotech communities so that breakthroughs in the laboratory can be translated more quickly to patients. Since our inception, our scientific research funding priorities have been focused on supporting diagnostic and therapeutic projects.

It is impossible to cure Lyme disease in every case without understanding how to diagnose it accurately. There are many reasons for this disease being difficult to identify—ticks are tiny, the EM skin rash is often misdiagnosed and symptoms overlap with other acute diseases like influenza. Most importantly, the widely used two tier diagnostic testing required for Lyme disease is currently the ELISA and Western Blot, which only detects the immune response (indirect detection) and not the pathogen itself. Because it can take at least 2-4 weeks for the body to generate antibodies, these tests have been shown to miss up to 70% of acute Lyme cases. These tests also do not detect other related Borrelia species, such as Borrelia miyamotoi), and cannot determine when the infection is eradicated.